Investors

Company Overview

We are a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, currently focused on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time.

Poxel's innovative pipeline of first-in-class products with disease-modifying mechanisms of action offers the potential for safer and more effective therapies for metabolic diseases. Our lead compound, Imeglimin, is in Phase 3 and the Trials of IMeglimin for Efficacy and Safety (TIMES) program for type 2 diabetes in Japan is currently ongoing as planned. The Phase 3 data results for the TIMES program is expected in 2019.  PXL770 has completed Phase 1 and is advancing into a Phase 2a proof of concept study for the treatment of NASH in early 2019. PXL065 (DRX-065) is in Phase 1 and anticipated to advance into a Phase 2 proof of concept study for the treatment of NASH in the second half of 2019.

Inception date: 2009
Employees: 40
Stock market: Euronext Paris - Compartment B
Ticker: POXEL
ISIN code: FR0012432516
First day of trading: February 6, 2015 (on Euronext)
Number of Shares Outstanding: 25,856,827

Contact Information

Investor Relations

Jonae Barnes
Senior Vice President, Investor Relations and Public Relations
T: +1 617-818-2985
Jonae.barnes@poxelpharma.com

Trophic Communications
Gretchen Schweitzer / Stephanie May
T: +49 89 238 877 34 or +49 171 185 56 82
may@trophic.eu

NewCap
Alexia Faure / Nicolas Merigeau
T: +33 1 44 71 94 94
poxel@newcap.eu

Sign up for email alerts

Be the first to receive breaking news

Sign up today